Suchen
Lipocine Inc
LPCNZur Watchlist hinzufügen
2.390USD
-0.070-2.85%
Handelsschluss 07/02, 13:00（ET）Kurse um 15 Minuten verzögert
17.87MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Lipocine Inc Unternehmen
Lipocine Inc. is a biopharmaceutical company leveraging its proprietary technology platform to enable effective oral delivery of therapeutics. The Company’s clinical development candidates include: LPCN 1154, oral brexanolone, for the treatment of postpartum depression, LPCN 2101, for the treatment of epilepsy, LPCN 2203, an oral candidate targeted for the management of essential tremor, LPCN 2401, an oral proprietary anabolic androgen receptor agonist for improved body composition in obesity management, and LPCN 1148, for the management of decompensated cirrhosis. It is also developing LPCN 1107, for the prevention of preterm birth, LPCN 1154, for rapid relief of postpartum depression, and LPCN 1144, for the treatment of metabolic dysfunction-associated steatohepatitis. Its product candidate, TLANDO, is a novel oral prodrug of testosterone containing testosterone undecanoate developed by the Company.
Lipocine Inc Informationen
BörsenkürzelLPCN
Name des UnternehmensLipocine Inc
IPO-datumMar 21, 2014
CEOPatel (Mahesh V)
Anzahl der mitarbeiter16
WertpapierartOrdinary Share
GeschäftsjahresendeMar 21
Addresse675 S Arapeen Dr Ste 202
StadtSALT LAKE CITY
BörseNASDAQ OMX - NASDAQ BASIC
LandUnited States of America
Postleitzahl84108-1295
Telefon18019947383
Websitehttps://www.lipocine.com/
BörsenkürzelLPCN
IPO-datumMar 21, 2014
CEOPatel (Mahesh V)
Führungskräfte von Lipocine Inc
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. John W. Higuchi
Mr. John W. Higuchi
Director
Director
203.80K
+79.98%
Dr. Mahesh V. Patel, Ph.D.
Dr. Mahesh V. Patel, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
160.68K
+31.12%
Dr. Nachiappan Chidambaram, Ph.D.
Dr. Nachiappan Chidambaram, Ph.D.
Senior Vice President - Research and Development
Senior Vice President - Research and Development
4.86K
+9.40%
Ms. Krista Fogarty
Ms. Krista Fogarty
Principal Accounting Officer, Corporate Controller
Principal Accounting Officer, Corporate Controller
1.40K
+23.64%
Dr. Richard Dana Ono, Ph.D.
Dr. Richard Dana Ono, Ph.D.
Independent Director
Independent Director
831.00
--
Mr. Jeffrey A. (Jeff) Fink
Mr. Jeffrey A. (Jeff) Fink
Independent Director
Independent Director
386.00
--
Dr. Jill M. Jene, Ph.D.
Dr. Jill M. Jene, Ph.D.
Independent Director
Independent Director
--
--
Mr. Spyros Papapetropoulos, M.D., Ph.D.
Mr. Spyros Papapetropoulos, M.D., Ph.D.
Lead Independent Chairman of the Board
Lead Independent Chairman of the Board
--
--
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. John W. Higuchi
Mr. John W. Higuchi
Director
Director
203.80K
+79.98%
Dr. Mahesh V. Patel, Ph.D.
Dr. Mahesh V. Patel, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
160.68K
+31.12%
Dr. Nachiappan Chidambaram, Ph.D.
Dr. Nachiappan Chidambaram, Ph.D.
Senior Vice President - Research and Development
Senior Vice President - Research and Development
4.86K
+9.40%
Ms. Krista Fogarty
Ms. Krista Fogarty
Principal Accounting Officer, Corporate Controller
Principal Accounting Officer, Corporate Controller
1.40K
+23.64%
Dr. Richard Dana Ono, Ph.D.
Dr. Richard Dana Ono, Ph.D.
Independent Director
Independent Director
831.00
--
Mr. Jeffrey A. (Jeff) Fink
Mr. Jeffrey A. (Jeff) Fink
Independent Director
Independent Director
386.00
--
Häufig gestellte Fragen
Wer sind die fünf größten Anteilseigner von Lipocine Inc?
Die fünf größten Anteilseigner von Lipocine Inc sind: Mr. John W. Higuchi
Wie viele Institutionen halten Anteile an Lipocine Inc (LPCN)?
Mit Stand vom 2026Q1 halten 45 Institutionen Anteile an Lipocine Inc, mit einem Gesamtmarktwert von etwa 2.08M, was 25.27% der Gesamtanteile entspricht. Im Vergleich zum 2025Q4 ist der institutionelle Aktienbesitz um 1533872.00 gestiegen.